Ramucirumab in stomach cancer: Added benefit not proven

Posted by on August 18, 2016 5:15 pm
Categories: health

Two studies submitted were unsuitable for the assessment of an added benefit because they did not meet the specifications on the comparator therapy and on the target population.

Leave a Reply

Your email address will not be published. Required fields are marked *